Key points {#Sec1}
==========

Recombinant DPPD provides a simple skin test for detecting TB patients.Recombinant DPPD performs similarly to crude PPD among HIV negative TB patients.Diagnostic capacity among HIV-positive individuals is improved with DPPD.

Introduction {#Sec2}
============

Tuberculosis (TB) was the primary cause of 1.3 million deaths in 2017, making it the second most common cause of death from infectious diseases (WHO [@CR46]). Estimates are that nearly 2 billion people latently infected with *Mycobacterium tuberculosis* and 5--10% of infected individuals will progress to TB disease during their lifetime (Getahun et al. [@CR17]; Houben and Dodd [@CR21]; WHO [@CR46]). *M. tuberculosis* infection is especially problematic in immune compromised individuals that have an increased likelihood of progression to disease such that TB is among the leading cause of death in HIV/AIDS patients. Accordingly, the World Health Organization (WHO) considers TB a global health emergency.

A wide variety of strategies are utilized to diagnose TB. Indirect methods such as chest X-rays are commonly used to confirm symptoms. Direct detection systems have included culture of *M. tuberculosis* from sputum samples, and modern technologies such as nucleic acid amplification tests (i.e., GeneXpert) have revolutionized the diagnosis of active TB by allowing faster generation of more sensitive and specific results that improve patient care (Boehme et al. [@CR4]; Nicol et al. [@CR33]). Given difficulties in sputum collection etc., these tests still have limited overall sensitivity, however, and even with generous subsidies and concessional pricing they remain too expensive for routine use in the majority of resource-limited settings.

Indirect detection tests that use anti-*M. tuberculosis* immune responses as a readout can be conducted in decentralized research settings and permit widespread surveillance programs. Assays that measure interferon (IFN)-γ secretion upon incubation of unfractionated blood with Mtb proteins (IFN-γ release assays; IGRA) have been developed (Arenas Miras Mdel et al. [@CR1]; Arias Guillen [@CR2]; Rangaka et al. [@CR37]). The cost and modest availability in most countries with limited resources have constrained the use of IGRA and prohibit their widespread use (Morrison et al. [@CR32]; Owusu-Edusei et al. [@CR34]; Pai et al. [@CR35]; Rangaka et al. [@CR37]). Even in the United States, where 2013 medical expenditures for TB-specific tests among the employer-based privately insured population were estimated to be \$53.0 million, private insurance claims data relating to TB testing indicated that IGRA were used far less often than tuberculin skin tests (TST) (13.7% versus 86.3%, respectively). TST were not only the most commonly used test, they were by far the least expensive (\$9) diagnostic strategy used (Owusu-Edusei et al. [@CR34]). Thus, both cost and practicality mean that skin tests are the more likely diagnostic strategy to be used, and many TB experts have favored the development of a skin test that could be more accurate for the diagnosis of active TB and LTBI (Pai et al. [@CR36]; Rangaka et al. [@CR37]; Rose et al. [@CR39]).

Clinicians have great familiarity with skin testing and TST has been the standard tuberculosis screening/surveillance tool for decades (Bass [@CR3]; Snider [@CR40]), generating results by inducing a measurable delayed type hypersensitivity (DTH) reaction at the site of intradermal injection of purified protein derivative (PPD; tuberculin). PPD is a precipitate of species-nonspecific molecules from filtrates of sterilized tuberculoid organism cultures and many varieties of PPD are actually in use. PPD-S2, the current US standard that was developed to address the eventual depletion of PPD-S (Villarino et al. [@CR44]), is used in the commercially available Aplisol^®^ and Tubersol^®^ (Jensen et al. [@CR23]). On June 6, 2019, Centers for Disease Control (CDC) announced an anticipated 3--10 month shortage of Aplisol, one of two purified-protein derivative (PPD) tuberculin antigens licensed in the US ([@CR10]). Tubersol, the other PPD licensed test, has also experienced regular shortages (CDC [@CR9]). Officials in 56% US jurisdictions have reported shortages of PPD TST antigen solutions in health departments (10 Tubersol only, four Aplisol only, and 15 both) to the extent that routine activities had been threatened or already curtailed (CDC [@CR8]).

We previously published preliminary results of a skin test for *M. tuberculosis* infection that was based on a novel recombinant protein produced from a gene unique to MTB. This protein, named DPPD on the basis of the first 4 amino acids of its N-terminus sequence, elicited delayed-type hypersensitivity (DTH) in 100% of *M. tuberculosis*-infected guinea pigs but not in animals sensitized with other *Mycobacteria* representative of the genus (Coler et al. [@CR12]). This small proof-of-concept study indicated that intradermal DPPD skin testing detected individuals exposed to MTB with higher sensitivity and specificity than had previously been reported with the TST using PPD (Campos-Neto et al. [@CR7]).

Here we report the findings from an open label evaluation of the sensitivity and specificity of DPPD among groups for whom testing results are traditionally poor, including those with prior BCG vaccination, active tuberculosis, and concurrent HIV infection.

Materials and methods {#Sec3}
=====================

Study design {#Sec4}
------------

This was a prospective open label clinical trial conducted in Salvador, Brazil. The study population was recruited at two sites: The University Hospital Professor Edgard Santos (HUPES) and the AIDS Reference Center (CREAIDS) of the state of Bahia, Brazil.

Study population {#Sec5}
----------------

A total of 375 individuals were screened, with 173 enrolled for skin test evaluations. Exclusions were predominantly made on the basis of lack of BCG scar and lack of microbial confirmation of TB. Participants were enrolled into one of 3 groups following their provision of informed consent (Table [1](#Tab1){ref-type="table"}). Group 1 (Healthy Controls with Prior BCG Vaccination) consisted of 95 persons \> 18 years of age who reported no respiratory symptoms, had a documented BCG vaccination scar on the right arm and were confirmed to be HIV negative. Group 2 (Active TB, without HIV infection; n = 40) and Group 3 (Active TB, with HIV infection; n = 38) included adult patients either without or with HIV infection who were treated for presumptive active TB. Chest radiographs were performed on all study participants, and patients presenting with palpable lymph nodes at study entry underwent needle aspiration or lymph node dissection to allow histopathologic evaluation of tuberculous involvement. Active TB was defined as fulfilling the following criteria: clinical signs and symptoms of pulmonary disease consistent with active tuberculosis; a chest radiograph prior to treatment consistent with active pulmonary TB; and a sputum sample that was positive for *M. tuberculosis* by either Ziehl--Neelsen staining or culture from Lowenstein-Jensen medium (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Active TB was further stratified into 3 clinical categories: (A) Pulmonary TB (PTB), defined by a chest radiograph consistent with TB; (B) Lymph node disease (LD), defined as a lymph node with histologic findings of acid-fast bacilli or growth of MTB from culture; and C) Disseminated TB (DTB), defined by presence of miliary pulmonary nodules and hepatosplenomegaly. Blood samples were collected from HIV-positive participants in Group 3 to quantify T cell subsets.Table 1Demographics of study groupsHealthyTB diseaseBCG immunizedHIV negativeHIV positiveN954038Gender Male421832 Female53226Age (years) Mean29.831.239.9 Min--max18--4718--5419--64Clinical presentation (n) Cavitary--204 Disseminated--933 Lymphadenopathy--3137

Antigen preparation and skin testing {#Sec6}
------------------------------------

Skin testing was conducted with either recombinant DPPD or Tubersol PPD Tuberculin (Connaught Laboratories Ltd, Willowdale, Ontario, Canada). Testing with DPPD was conducted following preparation as previously described (Campos-Neto et al. [@CR7]). Briefly, the recombinant DPPD protein was diluted with sterile PBS containing Tween 80 (0.0005%) as a stabilizer and 0.28% phenol as a preservative (i.e., the same contents as Tubersol PPD Tuberculin). The final solution was sterile filtered (0.2 m) and dispensed in 5 ml aliquots in sterile vials. Sterility and general safety testing were performed as specified by the regulations of the United States Food and Drug Administration. To perform the skin tests, 0.1 ml of each antigenic solution (with 1 µg of DPPD bioequivalent to 5 TU of Tubersol PPD Tuberculin) was injected intradermal (Mantoux technique) on each forearm. PPD was injected in the right arm and DPPD was injected in the left arm. Reactions were read by trained healthcare workers 48--72 h after administration, with induration measured in millimeters (mm) using standard methods (Dacso [@CR14]). Results are expressed in mm of transverse diameter of induration. Consistent with the instructions of the Tubersol product insert, induration ≥ 10 mm was considered positive in individuals from high-risk areas (i.e. the recruitment site used here) and induration ≥ 5 mm was considered positive in HIV-positive individuals.

Statistical analyses {#Sec7}
--------------------

Statistical analyses were conducted with GraphPad Prism (GraphPad Software, San Diego, CA). Based on the standard interpretation of r^2^ (coefficient of determination) values, correlation was considered weak when 0.3 \< r^2^ \< 0.5, moderate when 0.5 \< r^2^ \< 0.7, and strong when r^2^ \> 0.7 were found.

Results {#Sec8}
=======

Performance of DPPD in skin testing among target populations {#Sec9}
------------------------------------------------------------

We then evaluated the diagnostic capacity of DPPD as a skin test antigen by comparing against that of the gold standard, PPD. Indurations following PPD administration were generally greater than those observed following DPPD administration (Fig. [1](#Fig1){ref-type="fig"}). Although there was a moderate correlation between PPD and DPPD results (r^2^ = 0.6303), an induration of greater than 10 mm was observed in a lower proportion of healthy participants (i.e., those without active TB but with previous BCG vaccination) following administration of DPPD than following injection with PPD (13.6% versus 57.9%, respectively) (Fig. [1](#Fig1){ref-type="fig"}a). Thus, DPPD appears to provide more specific results than PPD.Fig. 1Skin testing with recombinant proteins. Healthy, BCG immunized individuals (n = 95) and TB patients, either negative (n = 40) or positive (n = 38) for HIV infection, were intradermally inoculated with 5 TU of Tubersol PPD Tuberculin or the bioequivalent 1 µg of DPPD. Induration was measured 24 h later. Results were determined to be positive when, consistent with CDC guidelines, induration \> 10 mm in HIV negative individuals and \> 5 mm in HIV positive individuals. In A, each dot represents an individual data point, while the solid line represents the correlation of results and the black dotted lines represent the 95% confidence intervals. The r^2^ value is indicated in the text insert. In B, per cent of each group falling within the indicated induration range is plotted

Among active TB patients, irrespective of if TB disease was of a cavitary, disseminated or lymphadenopathic presentation, all 40 HIV-negative individuals were positive at \> 10 mm induration following administration of either PPD or DPPD (Fig. [1](#Fig1){ref-type="fig"}b) and there was strong correlation between test results (r^2^ = 0.7689). These data indicate that DPPD performance is similar to that of PPD for the identification of HIV negative, TB patients.

Among patients with active TB and HIV co-infection, there was again a moderate correlation between the magnitude of response elicited by either PPD or DPPD (r^2^ = 0.6530). In contrast to results generated with PPD demonstrating that only half (19 of 38) of the HIV positive TB patients developed indurations greater than 5 mm (i.e., the recommended threshold for positive results in this population), in this group 89.5% (34 of 38) of participants developed indurations greater than 5 mm when challenged with DPPD. Importantly, none of the patients that were positive following PPD administration were negative following DPPD administration, indicating the improved sensitivity of DPPD among HIV-infected individuals.

Performance of skin testing relative to CD4 T cell status in HIV-infected individuals {#Sec10}
-------------------------------------------------------------------------------------

Given that a delayed type hypersensitivity response is elicited following intradermal administration of antigen, we hypothesized that CD4 T cell counts would be a major determinant of the induration size following skin testing in HIV positive TB patients. Accordingly, when we compared induration size against CD4 cell counts, we observed a strong correlation following testing with DPPD and a moderate correlation following testing with PPD (r^2^ = 0.7088 and 0.5457, respectively) (Fig. [2](#Fig2){ref-type="fig"}a). Induration size demonstrated only a weak correlation with CD8 cell counts (r^2^ = 0.3541 and 0.3034 for DPPD and PPD, respectively) (Fig. [2](#Fig2){ref-type="fig"}b). These data substantiate the performance of DPPD and indicate retained performance in HIV-infected individuals even with declining CD4 T cell counts.Fig. 2Correlation of T cell numbers with antigen-induced induration. CD4 and CD8 T cell counts were measured for TB patients that were HIV positive (n = 38) and are plotted against the skin induration measured 24 h after they were intradermally inoculated with either 5 TU of Tubersol PPD Tuberculin or the bioequivalent 1 µg of DPPD. Each dot represents an individual data point, while the solid line represents the correlation of results and the black dotted lines represent the 95% confidence intervals. The r^2^ value is indicated in the text insert. In B, per cent of each group falling within the indicated induration range is plotted

Discussion {#Sec11}
==========

Although TST remains the most widely used method for diagnosis of *M. tuberculosis* infection, PPD-based tests are limited by the reduced performance in populations that have been vaccinated with BCG and in individuals with immune deficiencies. Here we compared the performance of skin testing with recombinant DPPD against that of a standard PPD-based skin test in persons previously vaccinated with BCG and in HIV-infected patients presenting with clinical signs and symptoms consistent with active TB. Our data indicate that, relative to PPD, a skin test using DPPD can not only better distinguish TB among BCG vaccinees but has improved performance among HIV-infected TB patients. It is our belief that this advantage, along with the practical consideration that decentralized use of skin tests is attainable because they not require a laboratory component, provide a competitive advantage for the extended use of a DPPD-based skin test.

We developed a skin test based on the recombinant DPPD protein not only to address concerns surrounding sustainable, consistent production of PPD but also to provide a cost-effective alternative. PPD is a precipitate of species-nonspecific molecules from filtrates of sterilized tuberculoid organism cultures and many varieties of PPD are actually in use. Outside of North America, PPD RT23 is the most widely used PPD product, but PPD RT23 Mexico is used in Latin America, PPD-s is used in Japan and PPD-L is used in Russia (Comstock et al. [@CR13]; Kimura et al. [@CR26]; Rangel-Frausto et al. [@CR38]; Starshinova et al. [@CR41]; Yang et al. [@CR48]). PPD-S2, the current US standard that was developed to address the eventual depletion of PPD-S, is used in the commercially available Aplisol^®^ and Tubersol^®^ (Jensen et al. [@CR23]; Villarino et al. [@CR44]). Although results of testing with Aplisol^®^ and Tubersol^®^ were comparable with that of the original PPD-S, shifting use between Tubersol^®^ and Aplisol^®^ resulted in aberrations for reasons that are unclear (Gillenwater et al. [@CR18]; Mehta et al. [@CR31]; Villarino et al. [@CR43]). Mass spectrometry and molecular analyses identified over one hundred proteins from four different PPD, revealing that the heat shock proteins GroEl, GroEs, DnaK, and HspX that are conserved amongst most mycobacterial species contribute to roughly 60% of the total PPD protein content (Borsuk et al. [@CR5]; Cho et al. [@CR11]). It is believed that this wide mixture of mycobacterial proteins contributes to the inability of PPD-based TST to distinguish *Mtb* infection from either exposure to non-tuberculous mycobacteria or vaccination with BCG (Farhat et al. [@CR16]; Huebner et al. [@CR22]). The DPPD protein, encoded by *Rv0061*, is unique to the *Mtb* complex and is recognized by a strong DTH response in *Mtb*-infected guinea pigs and tuberculosis patients (Campos-Neto et al. [@CR7]; Coler et al. [@CR12]; Liu et al. [@CR28]). Data indicate that guinea pigs sensitized with crude mycobacterial antigen mixtures from each of *M. bovis*--BCG, *M. avium*, *M. kansasii*, *M. fortuitum*, *M. gordonae*, *M. chelonae*, *M. scrofulaceum*, *M. smegmatis*, *M. terrae*, and *M. vaccae* do not exhibit DTH responses against DPPD (Coler et al. [@CR12]). The data in BCG-immunized individuals reported here supports improved specificity of DPPD relative to PPD. Previous evaluation of 270 healthy individuals similarly found that DPPD was less likely to elicit induration than PPD-S (Tubersol^®^) (Campos-Neto et al. [@CR7]). It should be noted, however, that neither of these studies could discern if a positive DPPD result in healthy individuals was due to latent tuberculosis or a stronger BCG-induced response. This could potentially be delineated by incorporating a demographically similar BCG "naïve" population (such as individuals in the United States), but this introduces social and geographical (environmental mycobacteria) variables that makes them less than ideal comparators.

The use of TST for the diagnosis of active disease in HIV-infected individuals has been controversial with previous studies reporting reduced sensitivity in this population (Goldstein et al. [@CR19]; Graham et al. [@CR20]; Johnson et al. [@CR24]; Lifson et al. [@CR27]; Mamani et al. [@CR30]; Whittle et al. [@CR45]). It is therefore noteworthy that we also found that the DPPD appeared to be more sensitive for the detection of active TB in HIV-infected individuals than PPD. Magnitude of response to DPPD correlated strongly with CD4 T cell counts of HIV-infected patients. Even in the patients with CD4 T cell counts below 200 cells per ml (therefore fulfilling the definition of AIDS), 3 of 6 had positive induration of ≥ 5 mm in response to DPPD. This contrasted with the 1 of 6 that were positive upon evaluation with PPD. Expanded testing among individuals with defined CD4 T cell counts is required to validate this observation.

Modelling for elimination programs of diseases in which many people harbor infection without evidence of clinical symptoms emphasize the importance of detecting and treating these individuals (Cameron et al. [@CR6]; Dye et al. [@CR15]; Keeler et al. [@CR25]). Unless the chain of *M. tuberculosis* transmission is disrupted the global TB elimination targets are unlikely to be reached and, accordingly, the identification and treatment of latent TB infection (LTBI) is a critical component within the WHO End TB Strategy (Lonnroth and Raviglione [@CR29]; Uplekar et al. [@CR42]; WHO [@CR47]). In addition to a clear economic advantage, it is our belief that skin testing with DPPD presents a practical advantage over the IGRA and nucleic acid amplification tests (NAAT) have been developed (Arenas Miras Mdel et al. [@CR1]; Arias Guillen [@CR2]; Rangaka et al. [@CR37]). For example, a skin test is well suited for use in decentralized field studies or surveillance programs where even rudimentary laboratory support is lacking.

Our study does have some important limitations, perhaps foremost the evaluation of a relatively small number of patients in one geographic location. Therefore, building upon the data we present here, future evaluations of the DPPD-based skin test should include larger numbers of individuals at differing risk for LTBI. Testing in settings with differing exposure to environmental mycobacteria is also necessary, as well as direct comparison against other assays such as QuantiFERON and GeneXpert. In summary, the clinical data presented here demonstrates that fewer BCG immunized individuals respond to recombinant DPPD than crude PPD, patients with active TB respond strongly to DPPD skin test, and unlike PPD, the response to DPPD is preserved in HIV-infected TB patients. These results not only indicate that recombinant DPPD elicits a DTH response but also, most importantly, that it could replace the antigenic mixture represented by PPD while simultaneously providing improved performance in the HIV-affected communities that are highly at-risk for TB disease. This represents a major advance over the current strategy of skin testing with PPD that is used for TB detection in most countries.
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**Additional file 1: Figure 1.** Active TB was defined by clinical signs and symptoms of pulmonary disease consistent with active tuberculosis and a chestradiograph prior to treatment consistent with active pulmonary TB. Among such patients, a sputum sample was evaluated for the presence of M. tuberculosisby either Ziehl--Neelsenstaining (bacilloscopy) or outgrowth from culture in Lowenstein-Jensenmedium (culture). Per cent positive among HIV-negative and HIC-positive TB patients is shown.
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